[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-stenosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100647055","treatment-of-dysphagia-in-patients-with-dystrophic-epidermolysis-bullosa-with-budesonide-a-retrospective-bicentric-study-nice---paris-st-louis--necker-ebude-study-100647055",false,"NCT07684105","Treatment of Dysphagia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Retrospective Bicentric Study Nice - Paris St Louis \u002F Necker (EBUDE Study)","EBUDE","Inclusion Criteria:\n\nPatients of both sexes, of any age, with EBD in dominant or recessive form, treated for at least one month with budesonide for dysphagia resistant to usual treatments.\n\nA description of the clinical form must be available in the file. The patient must assess the benefit of treatment at 1 and\u002For 3 months of Budesonide.\n\nPatients must be affiliated with social security. For adults, consent of non-opposition is required, and for minors, non-opposition from one of the parents or the person holding parental authority must be collected.\n\nExclusion Criteria:\n\nNo precise clinical or biological diagnosis. Treatment with Budesonide \\\u003C 1 month. No evaluation criteria in the file \u002F Objection to the use of data (withdrawal of non-opposition)","ALL","1 Year",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"NA","Budesonide is an anti-inflammatory medication that works by decreasing the immune system's overreaction. In the treatment of eosinophilic esophagitis, especially with Jorveza or a preparation made in a pharmacy, it reduces the production of substances responsible for inflammation in the esophagus. This action reduces the accumulation of certain inflammatory cells (eosinophils) and thus improves the symptoms and lesions of the esophagus.\n\nDystrophic epidermolysis bullosa (EBD) is a rare genetic disease that makes the skin and mucous membranes very fragile. Blisters, sores and wounds can appear as a result of even minor trauma. Scarring is often abnormal and can cause tissue to shrink or shrink.\n\nTo date, only two studies involving a total of eight children with EBD have evaluated a budesonide-based preparation. The results show an improvement in swallowing difficulties (dysphagia) as well as good tolerance of the treatment. However, there are currently no published data regarding the use of Jorveza in the form of an orally disintegrating tablet in adults with EBD.\n\nThrough the follow-up of patients treated at the MAGEC reference center, specialized in rare genetic diseases of the skin and mucous membranes, we aim to evaluate the interest and effects of budesonide treatment in individuals with EBD presenting with dysphagia.",[26,27,28],"Recessive Dystrophic Epidermolysis Bullosa","Dysphagia","Esophageal Stenosis","NOT_YET_RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-06","ACTUAL",{"date":30,"type":20},{"date":36,"type":20},"2027-06-30",{"name":38,"class":39},"Centre Hospitalier Universitaire de Nice","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100568024","an-innovative-endoscopic-cap-for-dilating-benign-esophageal-strictures-in-children-100568024","NCT06675825","An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children","A Novel Endoscopic Attachment Cap for Benign Esophageal Stricture Dilation in Children: a Randomized, Multicentric Pilot Study.","BOUGIE-PED","Inclusion Criteria:\n\n* Age under 18 years of age\n* Indication for endoscopic esophageal dilation\n* Benign stenosis\n* Written Informed Consent signed by the subject and\u002For parent\u002Flegal representative (if applicable)\n\nExclusion Criteria:\n\n* Stenosis that cannot be treated endoscopically\n* Malignant esophageal strictures\n* Contraindications and limitations of the MD as described in the instructions for use","0 Years","18 Years",{"count":51,"type":20},40,[23],"The goal of this study is to find out if using the BougieCap device is a safe and effective way to stretch narrow areas in the esophagus (food pipe) in children. The main questions this study wants to answer are:\n\n* Does the BougieCap work well to treat narrow areas in the esophagus comparing with other methods to widen these narrow areas?\n* Is BougieCap easy to use and does it cause fewer problems or discomfort for children?\n\nResearchers will compare two groups: one using the BougieCap, and the other using traditional methods like balloon dilation, to see which one works better and is safer.\n\nParticipants will:\n\n* Answer questions about their symptoms before treatment, 24 hours after, and 14 days later.\n* Complete these questions during regular hospital visits or over the phone for the final check-up.\n\nThis study does not involve any extra risks or burdens for the participants.",[28,55],"Esophageal Dilation",[57,58,59],"esophageal stricture","esophageal dilation","pediatric gastroenterology","RECRUITING","2024-12-10",{"date":63,"type":33},"2024-12-11",{"date":65,"type":20},"2025-01",{"date":67,"type":20},"2026-12",{"name":69,"class":39},"University Children's Hospital, Zurich",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100566991","phase-1-esophageal-replacement-with-a-decellularized-human-esophagus-graft-100566991","NCT06662370","Esophageal Replacement With a Decellularized Human Esophagus Graft","Remplacement de l'œsophage Par Une Greffe d'œsophage Humain décellularisé","ESOGRAFT","Inclusion Criteria:\n\n* Age: 18 to 65\n* Caustic, traumatic, anastomotic, post-operative, radiation-induced or post-endoscopic (mucosal resection, submucosal dissection) benign esophageal stricture refractory to endoscopic dilatation.\n* For women: effective contraception for the entire duration of the study (from signature of consent to end of follow-up)\n* Affiliated or beneficiary of a social security scheme.\n* Free written consent signed by the participant and the investigator.\n\nExclusion Criteria:\n\n* Weight loss \\> 10% of body weight over last 3 months\n* Stenosis \\> 5 cm in length\n* Multiple strictures\n* Esophageal mouth stenosis\n* Anterior surgery close to the operative zone\n* Complete anterior omentectomy\n* Tumour stenosis or progressive tumour pathology\n* Non-stabilized psychiatric disorders\n* Participation in another interventional study\n* Pregnant or breast-feeding women\n* Women of childbearing age without effective contraceptive measures:\n\nAll women of childbearing age must have a negative pregnancy test prior to treatment and must agree to maintain highly effective contraception using contraceptive measures from the date of consent until 12 months due to the risks associated with anesthesia during endoscopy\n\n* Uncontrolled sepsis\n* Related to the transplant procedure\n\n  * ASA score ≥ 3,\n  * Severe respiratory insufficiency (FEV1 \\\u003C 1 L),\n  * Decompensated hepatic cirrhosis or presence of esophageal varices,\n  * Chronic renal insufficiency (creatinine \\> 1.25 N),\n  * Myocardial infarction less than 6 months old or progressive heart disease,\n  * WHO general condition \\> 2,\n  * Weight loss \\>20% not recovered after renutrition.\n* Contraindication to general anaesthesia, analgesics and antibiotics.\n* Conditions requiring long-term immunosuppressive or corticosteroid treatment.\n* Patients under curatorship or guardianship","65 Years",{"count":80,"type":20},24,[82,83],"PHASE1","PHASE2","The aim of the study is to analyze over a 12 month-period, the safety and the efficacy of a circumferentiel oesophageal replacement of the esophagus by a decelularized human esophagus, in 24 patient with a short esophageal stenosis refractory to endoscopic dilatations.",[28],[87,88,89,90,91,92,93],"Tissue engineering","Esophageal replacement","Esophageal stenosis","Caustic injury","Radiotherapy","Anastomotic stenosis","Esophageal stent","2024-10-25",{"date":96,"type":33},"2024-10-28",{"date":98,"type":20},"2024-11-01",{"date":100,"type":20},"2030-01-01",{"name":102,"class":39},"Assistance Publique - Hôpitaux de Paris"]